Patient-reported outcome measures in wild-type and variant cardiac transthyretin amyloidosis: the ITALY (impact of transthyretin amyloidosis on life quality) study
Estimation of the target population of a selective cardiac myosin inhibitor for hypertrophic obstructive cardiomyopathy: Real-life data from the French REMY register.